Literature DB >> 9874182

Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: role in drug induced neurotoxicity.

J S Gill1, A J Windebank.   

Abstract

Suramin is a polyanionic chemotherapeutic agent which causes severe peripheral neuropathy. The mechanisms of antineoplastic and neurotoxic activities are still poorly understood. Interference with growth factor receptor function has been suggested for suramin's chemotherapeutic function. Previous studies from our laboratory have demonstrated that suramin interfered with the function of nerve growth factor (NGF) and induced lysosomal storage defects within dorsal root ganglion neurons. Pentosan polysulfate (PPS) was used as another polyanionic agent, to compare these two cellular functions; NGF receptor interaction and disruption in glycolipid metabolism. Like suramin and NGF, PPS induced neurite outgrowth from the PC12 cell line which correlated with tyrosine phosphorylation of the high affinity NGF receptor (TrkA/gpl40) and ERK-1/MAP kinase. Ultrastructural studies of dorsal root ganglion exposed to PPS for various time periods were normal. This contrasted with suramin exposed cultures which consistently developed lamellar inclusion bodies (LIB) within 6 h. LIB formation with suramin treatment was associated with neuronal cell death, while PPS treatment did not cause any neurotoxic effects. These results indicated that PPS mimicked the effect of suramin on NGF receptors but did not cause similar accumulation of LIB. This suggested that the effect of polyanionic compounds on TrkA was not involved in LIB accumulation and subsequent induction of neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874182     DOI: 10.1023/a:1006051126333

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals.

Authors:  G Zugmaier; M E Lippman; A Wellstein
Journal:  J Natl Cancer Inst       Date:  1992-11-18       Impact factor: 13.506

2.  Heparin-binding growth factor blockade with pentosan polysulfate.

Authors:  S Swain; A Wellstein; B Parker; M Lippman; C Steakley; R DeLap
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

Review 3.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.

Authors:  C A Stein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

4.  Inhibition of axonal growth from sensory neurons by excess nerve growth factor.

Authors:  A M Conti; S J Fischer; A J Windebank
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

5.  Epidermal growth factor receptor expression and suramin cytotoxicity in vitro.

Authors:  S Olivier; P Formento; J L Fischel; M C Etienne; G Milano
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells.

Authors:  K J Pienta; W B Isaacs; D Vindivich; D S Coffey
Journal:  J Urol       Date:  1991-01       Impact factor: 7.450

7.  Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin.

Authors:  S Rees; G Constantopoulos; J A Barranger; R O Brady
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

8.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.

Authors:  R J Coffey; E B Leof; G D Shipley; H L Moses
Journal:  J Cell Physiol       Date:  1987-07       Impact factor: 6.384

9.  Suramin binds to platelet-derived growth factor and inhibits its biological activity.

Authors:  M Hosang
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

10.  Internucleosomal DNA cleavage and neuronal cell survival/death.

Authors:  A Batistatou; L A Greene
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.